Laurie Toich

Smoking and obesity account for a significant number of cancers worldwide.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

Innovative specialty drugs could result in more payers adopting value-based contracting.

Emergency departments are a safety net for low-income patients, many of whom may be at risk of HIV.

CAR T-cell therapies and biosimilars require new strategies compared with traditional drugs.

Overweight patients with BRCA mutations may be more likely to develop breast cancer.

The future of direct and indirect remuneration fees is in question, according to industry experts.

Immunotherapies for melanoma may be rendered ineffective by drug-resistant cells.

Health care providers should be aware of how HIV symptoms may affect menopausal women.

Understanding biosimilars will be crucial for pharmacists as interchangeability comes into play.

AbbVie and the International Myeloma Foundation will explore the outcomes of patients with multiple myeloma who have a specific genetic mutation.

A history of incarceration and homelessness could indicate an increased mortality risk among patients with HIV.

Breast cancer treatments may affect men differently than women.

Experts discuss expectations for home infusion and specialty pharmacy in 2018 at the MHA Business Summit.

Breast cancer survivors and insurance companies could gain a better understanding of mortality risk with a new model.

Social and public health providers linking patients to HIV services was found to increase retention in care.

Formal training may help health care teams work together more efficiently to improve outcomes.

Fuel source of cancer cells could impact their efficacy of CAR-T cell therapies for pediatric patients.

Treating mental health disorders may reduce the risk of progressive multiple sclerosis.

Tamoxifen and raloxifene may improve muscle function among patients with muscular dystrophy.

Treatment with siponimod reduced brain volume loss by 23% in patients with secondary progressive multiple sclerosis.

Kinesin family member 5A mutations may cause amyotrophic lateral sclerosis.

Women with a prior chlamydia infection could have twice the risk of ovarian cancer.

The FDA has approved ILUMYA (tildrakizumab-asmn, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis.

Show us how you and your pharmacy celebrate National Pharmacist Day by using #APharmacistIs on social media.

Risankizumab treats moderate to severe chronic plaque psoriasis.

New research indicates that high consumption of certain dairy products may either increase or decrease the risk of developing breast cancer, depending on the food.